This inventor holds 34 USPTO granted patents and 14 published patent applications and 4 EPO patents, primarily in Nanoparticle Technology. Top assignees: Massachusetts Institute of Technology, Samsung Electronics Co., Ltd., Dana-Farber-Cancer Institute Inc.. Active years: 2006-2025.
Location History:
- Cambridge, MA (US) (2022)
- Newton, MA (US) (2006 - 2024)
Company Filing History:
33 out of 8,576 
5 out of 132,108 
1 out of 1,265 
Years Active: 2006-2025
Areas of Expertise:
Title: **Paula T Hammond: Innovator in Nanomedicine**
Introduction
Paula T Hammond, based in Newton, MA, is a prominent inventor and innovator in the field of nanomedicine. With an impressive portfolio of 33 patents, she has made significant contributions to cancer treatment through her research in lipid-based nanoparticles. Her work has the potential to transform therapeutic strategies and improve patient outcomes.
Latest Patents
Hammond's latest patents include groundbreaking innovations such as the identification of Solute Carrier Family 46 Member 3 (SLC46A3) as a biomarker for lipid-based nanoparticle cancer therapy. This marker is crucial for predicting the affinity between lipid-based nanoparticles and cancer cells, revealing that tissues with lower SLC46A3 expression levels exhibit a greater uptake of these nanoparticles. This inverse relationship not only provides insights into therapeutic applications for cancer treatment and diagnostics but also enhances patient stratification in clinical trials involving lipid-based nanotherapeutics.
Another significant patent focuses on the development of layer-by-layer nanoparticles designed for cytokine therapy in cancer treatment. These novel particles are engineered to deliver cytokines, such as IL-12, effectively by non-covalently binding them to liposomes, which are further coated with polyelectrolytes. This innovation aims to enhance the delivery and efficacy of cytokines in targeting cancer cells.
Career Highlights
Throughout her career, Paula T Hammond has collaborated with esteemed institutions, including the Massachusetts Institute of Technology (MIT) and Samsung Electronics Co., Ltd. Her role at these institutions has allowed her to pioneer research that bridges the gap between engineering and life sciences, particularly in the development of advanced therapeutic technologies.
Collaborations
Hammond has worked alongside notable colleagues, including Sun Hwa Lee and Angela M Belcher. These collaborations have facilitated a multidisciplinary approach to her research, enabling the integration of differing perspectives and expertise in nanotechnology and cancer therapy.
Conclusion
Paula T Hammond continues to be a leading force in the advancement of nanomedicine, particularly in the realm of cancer therapies. With her extensive patent portfolio and ongoing research, she is poised to make lasting impacts that could change the landscape of cancer diagnostics and treatment, paving the way for more effective and personalized medicine.